In a previous study, the effect of ALDH1 on clinical outcomes was found to be stronger in a lymph node metastasis-positive subgroup and a neoadjuvant chemotherapy setting [2, 14, 19, 23, 29, 30, 35]. The gene discussed is ALDH1A1; the disease is metastatic malignant neoplasm in the lymph nodes.